NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 01 04:00PM ET
0.3905
Dollar change
-0.0055
Percentage change
-1.39
%
Index- P/E- EPS (ttm)-1.22 Insider Own23.95% Shs Outstand58.40M Perf Week-1.14%
Market Cap22.81M Forward P/E- EPS next Y-1.11 Insider Trans0.00% Shs Float44.43M Perf Month-4.52%
Enterprise Value-9.00M PEG- EPS next Q-0.29 Inst Own18.51% Short Float9.28% Perf Quarter12.60%
Income-61.88M P/S2.07 EPS this Y19.44% Inst Trans-39.52% Short Ratio7.80 Perf Half Y-38.98%
Sales11.00M P/B41.68 EPS next Y4.60% ROA-97.07% Short Interest4.12M Perf YTD-33.95%
Book/sh0.01 P/C0.70 EPS next 5Y8.86% ROE-246.21% 52W High2.53 -84.53% Perf Year-73.44%
Cash/sh0.55 P/FCF- EPS past 3/5Y19.57% -10.97% ROIC-11311.88% 52W Low0.24 62.71% Perf 3Y-89.00%
Dividend Est.- EV/EBITDA- Sales past 3/5Y253.03% 16.17% Gross Margin92.11% Volatility8.74% 12.57% Perf 5Y-
Dividend TTM- EV/Sales-0.82 EPS Y/Y TTM51.11% Oper. Margin-610.00% ATR (14)0.05 Perf 10Y-
Dividend Ex-Date- Quick Ratio2.35 Sales Y/Y TTM- Profit Margin-562.51% RSI (14)44.77 Recom1.67
Dividend Gr. 3/5Y- - Current Ratio2.35 EPS Q/Q45.53% SMA20-8.90% Beta0.90 Target Price5.50
Payout- Debt/Eq1.00 Sales Q/Q- SMA50-9.30% Rel Volume0.33 Prev Close0.40
Employees76 LT Debt/Eq0.00 EarningsMay 06 AMC SMA200-56.76% Avg Volume528.87K Price0.39
IPODec 16, 2020 Option/ShortYes / Yes EPS/Sales Surpr.11.35% - Trades Volume175,592 Change-1.39%
Date Action Analyst Rating Change Price Target Change
Nov-13-24Downgrade H.C. Wainwright Buy → Neutral
Sep-15-22Initiated JMP Securities Mkt Outperform $17
May-05-22Downgrade Credit Suisse Outperform → Neutral $35 → $5
Mar-21-22Initiated H.C. Wainwright Buy $25
Oct-15-21Resumed BTIG Research Buy $68
Jun-28-21Initiated ROTH Capital Buy $75
May-05-21Resumed Credit Suisse Outperform $68
Apr-26-21Resumed Credit Suisse Outperform $68
Jan-11-21Initiated JP Morgan Overweight $45
Jan-11-21Initiated Jefferies Buy $51
Jun-02-25 08:00AM
May-07-25 03:21AM
May-06-25 04:05PM
Apr-30-25 08:00AM
Apr-29-25 08:00AM
08:00AM Loading…
Apr-24-25 08:00AM
Apr-23-25 10:05AM
Mar-28-25 12:45PM
03:04AM
Mar-27-25 06:18PM
04:05PM
Mar-20-25 08:00AM
Mar-19-25 08:00AM
Jan-02-25 12:00PM
Dec-20-24 09:00AM
08:00AM Loading…
Dec-16-24 08:00AM
Dec-10-24 08:00AM
08:00AM
Nov-08-24 04:03PM
Nov-07-24 04:01PM
Oct-31-24 08:00AM
Oct-20-24 04:06PM
Oct-09-24 05:57PM
Oct-04-24 09:05AM
Oct-01-24 08:00AM
Sep-23-24 07:30AM
Sep-16-24 08:00AM
Sep-09-24 08:00AM
Aug-28-24 08:00AM
Aug-08-24 04:05PM
08:00AM Loading…
Aug-01-24 08:00AM
Jul-31-24 01:11PM
Jul-25-24 05:39PM
Jul-24-24 12:54PM
Jul-23-24 08:00AM
Jun-27-24 08:00AM
May-29-24 08:00AM
May-23-24 05:05PM
May-15-24 08:18AM
07:01AM
May-14-24 08:57PM
04:05PM
May-08-24 08:00AM
May-07-24 08:00AM
May-06-24 09:14AM
08:00AM
Apr-24-24 04:35PM
Mar-27-24 10:07AM
07:56AM
Mar-26-24 09:54PM
05:33PM
04:01PM
Mar-19-24 08:00AM
Mar-07-24 08:00AM
Dec-20-23 08:00AM
Dec-13-23 08:00AM
Dec-06-23 08:00AM
Dec-05-23 08:00AM
Nov-30-23 08:00AM
Nov-28-23 08:00AM
Nov-12-23 09:24AM
Nov-07-23 04:01PM
Nov-06-23 04:05PM
Oct-12-23 07:30AM
Oct-10-23 07:30AM
Sep-06-23 08:00AM
Aug-03-23 04:01PM
06:48AM
Aug-02-23 11:31AM
Aug-01-23 04:01PM
Jul-25-23 08:00AM
Jul-07-23 07:09AM
Jun-26-23 08:00AM
May-31-23 08:00AM
May-11-23 04:01PM
May-08-23 04:05PM
May-04-23 08:00AM
Apr-29-23 09:29AM
Mar-31-23 06:36AM
Mar-27-23 07:12AM
Mar-24-23 11:31AM
Mar-23-23 04:05PM
Mar-16-23 08:00AM
Feb-27-23 08:07AM
Feb-23-23 08:00AM
Jan-25-23 07:10AM
Jan-10-23 08:00AM
Dec-29-22 04:05PM
Dec-22-22 08:00AM
Dec-08-22 08:54AM
Dec-01-22 09:55AM
Nov-15-22 09:55AM
Nov-11-22 08:38AM
Nov-08-22 08:00AM
Nov-04-22 11:15AM
09:08AM
Nov-03-22 04:01PM
Oct-27-22 08:00AM
Sep-23-22 09:15AM
Sep-21-22 10:14AM
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.